Biomarkers for Immunotherapy

Immune checkpoint inhibitor (ICI) therapy has been approved for several solid tumors, including non-small cell lung cancer. ICIs have shown unprecedented durable responses and higher response rates than chemotherapy in selected patients. The development of biomarkers that serve as predictors of response is crucial for treatment selection. Evidence suggests that the response to immunotherapy depends on tumor genomics and the interactions with the immune system and the tumor microenvironment. This article reviews the data supporting the use of these biomarkers to optimize patient selection for these therapies and explores biomarkers that are the focus of ongoing research.